Erectile Dysfunction: New Concepts in Diagnosis, Prevention and Management
Supported by an educational grant from
This advanced postgraduate course examines the causes and treatment modalities of erectile dysfunction (ED) most often seen by urologists. The diagnosis and treatment of ED has undergone a revolution in the past decade. New treatment modalities have emerged to assist the urologist in treating the large number of patients suffering from this difficult condition. With the advent of new oral medications it is important to understand the capabilities of these different phosphodiesterase-5 (PDE-5) inhibitors, their differences, and the pharmacologic action of each agent. Because urologists are often confronted with the most difficult patients with ED, it is important for the urologist to understand treatment of patients with ED associated with vascular disease, difficult to treat patients such as those following prostate cancer treatment whether radiation or surgery, and initial medical treatment of Peyronie’s disease. The relationship of prostatic disease and cardiovascular risk factors and ED continue to evolve. This course will present the most recent data on oral medications and compare the PED-5 inhibitors and discuss new centrally acting agents soon to be available in a case-based format. Medical therapy of Peyronie’s disease and patients with severe ED following treatment of carcinoma of the prostate will be highlighted. The concept of medical prophylaxis and change in PDE-5 inhibitors will be discussed. Interactive case discussions on ED and the interaction of medications, common cardiovascular, neurologic and post surgical conditions will facilitate faculty/audience interaction.
Objectives: After attending this course, the participants should be able to:
discuss the physiology and pathophysiology of erectile function and dysfunction in men at risk for this difficult condition
identify similarities, differences, and outcomes with the various PDE-5 inhibitors currently available and compare with CNS agents in trials
treat patients with ED following management of carcinoma of the prostate
cite alternatives of medical treatment for patients with Peyronie’s disease
outline a series of approaches for patients with difficult to treat ED unresponsive to initial therapy with oral agents
If you wish to apply for CME for these lectures, please log in first.